Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics

Navidea Biopharmaceuticals, Inc. (NAVB): $1.30

0.02 (+1.56%)

POWR Rating

Component Grades













Add NAVB to Watchlist
Sign Up

Industry: Biotech


of 493

in industry


  • NAVB scores best on the Sentiment dimension, with a Sentiment rank ahead of 67.33% of US stocks.
  • NAVB's strongest trending metric is Value; it's been moving up over the last 176 days.
  • NAVB ranks lowest in Quality; there it ranks in the 10th percentile.

NAVB Stock Summary

  • With a market capitalization of $38,641,268, Navidea Biopharmaceuticals Inc has a greater market value than just 6.25% of US stocks.
  • With a price/sales ratio of 55.17, Navidea Biopharmaceuticals Inc has a higher such ratio than 95.59% of stocks in our set.
  • With a year-over-year growth in debt of -63.13%, Navidea Biopharmaceuticals Inc's debt growth rate surpasses merely 6.37% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Navidea Biopharmaceuticals Inc are SCYX, MOSY, FLUX, UTSI, and EMAN.
  • Visit NAVB's SEC page to see the company's official filings. To visit the company's web site, go to

NAVB Valuation Summary

  • In comparison to the median Healthcare stock, NAVB's price/sales ratio is 1394.74% higher, now standing at 56.8.
  • NAVB's price/earnings ratio has moved down 11.9 over the prior 243 months.
  • NAVB's price/sales ratio has moved up 55.5 over the prior 243 months.

Below are key valuation metrics over time for NAVB.

Stock Date P/S P/B P/E EV/EBIT
NAVB 2021-08-31 56.8 8.7 -4.1 -3.8
NAVB 2021-08-30 56.8 8.7 -4.1 -3.8
NAVB 2021-08-27 56.1 8.6 -4.1 -3.7
NAVB 2021-08-26 55.0 8.4 -4.0 -3.6
NAVB 2021-08-25 54.0 8.3 -3.9 -3.6
NAVB 2021-08-24 56.1 8.6 -4.1 -3.7

NAVB Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at 14.5%.
  • Its year over year net cashflow from operations growth rate is now at -26.34%.
  • The year over year revenue growth rate now stands at 14.24%.
NAVB's revenue has moved down $12,376,884 over the prior 67 months.

The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.872423 -10.66532 -11.9495
2021-03-31 0.882478 -10.285 -11.67886
2020-12-31 0.915013 -8.173793 -11.38558
2020-09-30 0.815061 -8.350325 -11.15377
2020-06-30 0.783483 -8.062057 -10.92298
2020-03-31 0.772474 -8.140716 -11.19276

NAVB Stock Price Chart Interactive Chart >

Price chart for NAVB

NAVB Price/Volume Stats

Current price $1.30 52-week high $3.15
Prev. close $1.28 52-week low $1.21
Day low $1.26 Volume 23,000
Day high $1.33 Avg. volume 177,668
50-day MA $1.57 Dividend yield N/A
200-day MA $1.79 Market Cap 39.24M

Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.

NAVB Latest News Stream

Event/Time News Detail
Loading, please wait...

NAVB Latest Social Stream

Loading social stream, please wait...

View Full NAVB Social Stream

Latest NAVB News From Around the Web

Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Earnings Conference Call November 10, 2021, 05:00 PM ET Company Participants Mike Rosol - Chief Medical Officer Erika Eves - Vice President of Finance and Administration Conference Call Participants Presentation Operator Greetings. Welcome to the Navidea Q3 2021 Earnings Conference Call. [Operator Instructions] Please...

SA Transcripts on Seeking Alpha | November 11, 2021

Navidea Biopharm EPS beats by $0.03

Navidea Biopharm (NYSE:NAVB): Q3 GAAP EPS of -$0.08 beats by $0.03. Revenue of $0.97M (+259.3% Y/Y) Press Release...

Seeking Alpha | November 10, 2021

Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should Know

Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 4, 2021

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

DUBLIN, Ohio, November 03, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, November 10, 2021 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2021.

Yahoo | November 3, 2021

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

DUBLIN, Ohio, October 26, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of

Yahoo | October 26, 2021

Read More 'NAVB' Stories Here

NAVB Price Returns

1-mo -13.91%
3-mo -20.73%
6-mo -26.14%
1-year -45.83%
3-year -65.79%
5-year -91.77%
YTD -39.53%
2020 70.63%
2019 -37.00%
2018 -72.22%
2017 -43.75%
2016 -51.88%

Continue Researching NAVB

Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:

Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7653 seconds.